CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

BACKGROUND: A phase I/II study and subsequent phase III study (MPACT) reported significant correlations between CA19-9 decreases and prolonged overall survival (OS) with nab-paclitaxel plus gemcitabine (nab-P + Gem) treatment for metastatic pancreatic cancer (MPC). CA19-9 changes at week 8 and poten...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Ann Oncol
Glavni autori: Chiorean, E. G., Von Hoff, D. D., Reni, M., Arena, F. P., Infante, J. R., Bathini, V. G., Wood, T. E., Mainwaring, P. N., Muldoon, R. T., Clingan, P. R., Kunzmann, V., Ramanathan, R. K., Tabernero, J., Goldstein, D., McGovern, D., Lu, B., Ko, A.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2016
Teme:
Original Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4803454/
https://ncbi.nlm.nih.gov/pubmed/26802160
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdw006
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items